Partner Headlines - AMGN

  1. What Is Beyond Vision-Loss Blockbuster For Regeneron?

    IBD
  2. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD
  3. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's ...

    Benzinga
  4. Biotech Short-Sellers Prefer Amgen To Gilead Sciences

    Benzinga
  5. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  6. ProShares Releases 2 New Leveraged Biotech ETFs

    Benzinga
  7. An Ebola-Fighting Portfolio For The Present...And The Future

    Benzinga
  8. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  9. Biotech ETFs Hit New 2015 Highs

    Benzinga
  10. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  11. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  12. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD
  13. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  14. FDA Cautious On New Drugs

    IBD
  15. Amgen Cholesterol Drug Repatha Wins FDA Panel Vote

    IBD
  16. Regeneron, Amgen Fall On Cholesterol Drug Worries

    IBD
  17. FDA Panel Backs Regeneron

    IBD
  18. Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

    IBD
  19. FDA Looking at New Drugs to Lower "Bad" Cholesterol

    FoxBusiness
  20. FDA weighs cholesterol fighter

    IBD
  21. Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

    IBD
  22. FDA: Cholesterol Drug Works

    IBD
  23. Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

    IBD
  24. PRIMECAP Sells Portions of Its Top Two Stakes

    GuruFocus
  25. Amgen And AstraZeneca's Deal On Psoriasis Drug Faces Termination

    GuruFocus
  26. 5 Drugs That Could Be Summer Blockbusters

    IBD
  27. CNBC's Stock Pops & Drops From May 26

    Benzinga
  28. Amgen's Cholesterol Fighting Drug Receives EU Approval

    GuruFocus
  29. Amgen Down After Suicides Kill AstraZeneca Deal

    IBD
  30. Morgan Stanley Found This 'Unexpected Negative' At Amgen

    Benzinga
  31. 5 Drugs That Could Be Summer Blockbusters

    IBD
  32. Amgen gets cholesterol edge

    IBD
  33. Health Care Sector Delivers Healthy Q1 Results

    IBD
  34. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  35. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  36. The Best And Worst ETFs Of The Week Amid Biotech Rebound

    Benzinga
  37. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  38. Crouching Tigers, Hidden Assets - Smead Capital Management

    GuruFocus
  39. Amgen's Decline Could Be A Good Thing

    Benzinga
  40. Should Amgen's T-Vec Results Be Questioned?

    Benzinga
  41. Amgen drug misses fast track

    IBD
  42. Why Baird Is Upgrading DaVita Healthcare

    Benzinga
  43. Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm

    IBD
  44. Amgen Reports An Upbeat Q1 Earnings

    GuruFocus
  45. Stocks Strengthen; Tesla Motors Rises On Battery News

    IBD
  46. Stocks Mildly Higher; China Nods To Visa, MasterCard

    IBD
  47. Amgen, Illumina Crush Views

    IBD
  48. Amgen, Illumina Earnings Hot, Intuitive Surgical Not

    IBD
  49. Amgen Tops Q1 Expectations, Shares Gain

    Benzinga
  50. Strategist: Amgen To Move 3% On Q1 Earnings News

    Benzinga
  51. What The Street...And The Crowd Are Watching At Amgen Before ...

    Benzinga
  52. Amgen Inc.'s First Quarter Earnings Preview - What Could Be In ...

    GuruFocus
  53. 5 Biotech Earnings Under The Microscope This Week

    Benzinga
  54. Amgen's First Drug For Cardiovascular Disease Gets The Green ...

    GuruFocus
  55. Why Amgen Might Start To Turn Around

    Benzinga
  56. Amgen Has A Big Launch Coming Up

    Benzinga
  57. AMGEN

    IBD
  58. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD
  59. Short Sellers Come Back To Biotech Stocks

    Benzinga
  60. Making Money With Charles Payne: 02/25/15

    FoxBusiness
  61. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  62. A Look At Dan Loeb's Diversified 13F

    Benzinga
  63. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  64. Short Sellers Retreat From Biotech Stocks

    Benzinga
  65. FDA Advisory Committee To Review Amgen's Talimogene Laherparepvec

    Benzinga
  66. Dan Loeb Offers Mea Culpa For 'Mediocre' Returns

    Benzinga
  67. Dan Loeb Fourth Quarter Investor Letter

    GuruFocus
  68. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  69. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  70. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD
  71. Nuveen's Bob Doll Runs Several Top Funds

    IBD
  72. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  73. Credit Suisse Sees Solid Q4 For Amgen

    Benzinga
  74. Amgen Q4 earnings top views

    IBD
  75. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  76. Making Money With Charles Payne: 01/27/15

    FoxBusiness
  77. Amgen Beats Q4 Expectations

    Benzinga
  78. Stocks Weaken Late; Apple Jumps After Hours

    IBD
  79. Earnings Scheduled For January 27, 2015

    Benzinga
  80. 5 Big Biotech Earnings Releases To Watch This Week

    Benzinga
  81. Can CAR-T Therapy Live Up To The Biotech IPO Hype?

    IBD
  82. New Guru Jana Partners' Newest Stock Buys

    GuruFocus
  83. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  84. Cholesterol Drug Costs Eyed

    IBD
  85. Amgen's Decline May Be Linked To Comments Of Express Script's ...

    Benzinga
  86. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  87. Regeneron rises on drug data

    IBD
  88. Crude Awakening As Energy Squeezes Overall Q4 Profit

    IBD
  89. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  90. Drugs May Be Blockbusters

    IBD
  91. Weekly Review Shows Five Industries Gain In December

    IBD
  92. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  93. Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy

    GuruFocus
  94. Kite Pharma Gets Stock Price Increase Post Amgen Deal

    IBD
  95. UPDATE: Barclays Initiates Coverage On Amgen

    Benzinga
  96. Amgen, Kite Reach Cell Deal

    IBD
  97. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  98. Morgan Stanley Issues Wave Of Pharma & Medical Device Upgrades, ...

    Benzinga
  99. Kite Pharma Up On Amgen Cancer Parternship

    IBD
  100. Stocks Drop 1% In Rising Volume; Visa Falls 1%

    IBD
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!